Gilead and Novo Nordisk expand NASH deal with new study; Pfizer out-licenses ADCs to a biotech startup
Pfizer has out-licensed a pair of antibody-drug conjugates to Cambridge, MA-based Pyxis Oncology.
Pyxis is handing over an unspecified upfront payment, milestones and a chunk of equity to Pfizer, and also gains rights to Pfizer’s ADC platform, “including various payload classes, linker technology and site-specific conjugation techniques for the future development of additional ADCs.”
Ronald Herbst, the CSO at Longwood-funded Pyxis, said:
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.